Cybin Inc. (NYSE:CYBN) and Kernel, two companies that undertook a joint feasibility study to evaluate the effects ketamine has on blood flow in the brain in late March, announced their results.
In a video shared by Kernel, the company’s CEO and founder, Bryan Johnson, acted as the first pilot participant. He was administered intramuscular ketamine and the hemodynamics of his brain were measured. In his case, as well as for all other participants, the study took 11 days. During the first 5 days, a baseline brain activity was recorded, with dosing on day 6 and follow-up sessions for the remainder.
